Yes, people are taking notice of HGSI and the entire sector. Today's impetus was probably concerning the deals Pfizer made with Celera and Incyte:
<<New York, Nov. 22 (Bloomberg) -- Pfizer Inc., the No. 2 U.S. drugmaker, will buy genetic information from PE Corp.-Celera Genomics Group, a gene-mapping company, and collaborate on research under a five-year agreement.>>
<<PALO ALTO, Calif., Nov 22 (Reuters) - Incyte Pharmaceuticals Inc <INCY.O> Monday said it expanded its collaboration with Pfizer Inc <PFE.N> in a deal that will enable it to accelerate its gene sequencing work and analyze all gene sequences as potential drug targets.>>
As far as the genomics stocks being the "Internet stocks of last year", well, maybe. Neither the Internet stocks (certainly at the start of their run a few years ago) nor the genomic stocks will make big money for years. HGSI is further along than the other "clinical" genomic companies and still will have 2 or 3 years to go until their first drugs come to market. Still, the concept of genomically derived drugs is at least as compelling as the Internet-related businesses and so the HGSI share price may continue to run without any hope of earnings for years. AOL, the most mature Internet company, has a PE of 240 and a market cap of over 180 billion: HGSI's market cap of 2.5 billion is tiny in comparison. We are getting ahead of ourselves though; the ultimate result will depend on the successful development, testing and marketing of the drugs.
|
